The Discovery of Endorphins

For years it had been suspected that opiates had specificbinding sites in the brain. There were several attempts tolocate these sites, but the existing technologies were unable todistinguish between the non specific binding to tissue and thespecific binding to receptors. It must be mentioned here thatthe first attempt to actually measure specific opiate bindingwas in the laboratory of Dr. Vincent Dole (Ingolia & Dole,1970). Although the technology was not available at that timehe laid the foundations for the discovery of opiate receptors.

By the early 1970s scientific technology had evolved to thepoint where the discovery of opiate binding sites seemed almostinevitable. The first to shake the scientific community wasSolomon Snyder and his student, Candice Pert of John HopkinsUniversity (Pert & Snyder, 1973). Using a technique developedby Avram Goldstein of Stanford University, Snyder and Pertlocated the elusive opiate receptor (Goldstein, Lowney & Pal,1971). That same year two other groups headed by Eric J. Simonof New York University (1973) and Lars Terenious in Uppsala,Sweden (1973) demonstrated specific opiate binding in nervoustissue. The treasure Hunt had begun! “For why,” Goldsteinasked, “would God have made opiate receptors unless he had alsomade an endogenous morphine-like substance?”

In the mid-1960s Choh Li of the University of California atBerkeley had isolated a pituitary hormone which he namedB-Lipotropin (Li, 1964). He noted that one portion of thishormone had analgesic properties. One year after the discoveryof the receptor sites John Hughes at the laboratory of HansKosterlitz in Aberdeen, Scotland reported the existence of anendogenous morphine-like substance which they later purified andnamed Enkephalin for “in the head” (Hughes, 1975a; Hughes,1975b; Kosterlitz, 1976) The Aberdeen group recognized that thepeptide sequence of Enkephalin was contained within Li’s B-Lipotropin. Li would later name the other endogenousmorphine-like peptides, which also come from his pituitaryhormone, Endorphin for “morphine within.”

Today the term opioid is used for all endogenous morphine-likesubstances, including Dynorphin another brain opioid peptidesystem found by Avram Goldstein (Goldstein, Tachibana, Lowney,Hunkapiller & Hood, 1979). Other psychoactive peptides have beendiscovered and isolated using the techniques developed in theselaboratories. In 1978 Solomon Snyder, John Hughes and HansKosterlitz shared the Lasker Award for their discoveries. Paralleling the discovery of Enkephalins, Endorphins and opiatereceptors have been advances in the field of neuroscience. These advances have led to many exciting discoveries andgenerated a new interest in the functioning of the brain. Wehave entered a new era in our understanding of human behavior.


References

  • Goldstein, A.; Lowney, L.I. and Pal, B.K.
    Stereospecific andnon stereospific interactions of the morphine congenerlevorphanol in sub cellular fractions of mouse brain.

    Proceedings of the National Academy of Science USA 1971 68:1742-1747.

  • Goldstein, A.; Tachibana, S.; Lowney, L.I.; Hunkapiller M. and Hood, L.
    Dynorphin-(1-13), an extraordinarily potent opioid

Similar Posts

  • Review Guidelines for the Federation of State Medical Boards

    Admin 10/20/2022

    NAMA’s Comments to the Federation of State Medical Boards Prepared by: National Alliance of Methadone Advocates 435 Second Avenue New York, NY 10010 Phone: (212) 595-6262 Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office Section I Preamble Paragraph 2 The second sentence should also include the fact that Medical Maintenance has been…

  • Letter

    Admin 08/13/2021

    Letter, November 9, 2004 Sheriff Chris Curry; Sir, I have read the articles that state you are adiment against having a methadone treatment center in your county. May I point out sir that as a law enforcement officer this could do nothing but help your already rising arrest record for drug related crime in Shelby…

  • COVID-19 Resources

    Admin 01/17/2022

    CORONAVIRUS Resources We’ve gathered some resources from around the nation to support organizations, employees, and individuals through the COVID-19 pandemic. Resources from the Substance Abuse & Mental Health Services Administration. Relevant resources from other federal agencies. STATE RESOURCES Relevant resources from state agencies arount the nation. OTHER AGENCIES Relevant resources from non-government agencies. SAMHSA’s COVID-19…

  • Pre-conference Meeting Sunday, October 7th Unifying the Treatment Community

    Admin 01/11/2022

    Pre-conference Meeting Sunday, October 7th Unifying the Treatment Community This special pre-conference meeting is divided into two sessions – a morning and afternoon session. These sessions have been developed by the Advocacy Coalition: National Alliance of Methadone Advocates (NAMA), Advocates for Recovery through Medicine (ARM), Advocates For the Integration of Recovery and Methadone (AFIRM), Virginia…

  • Pharmacological Agents Interacting With Methadone

    Admin 09/10/2021

    Information on NAMA’s website is not intended as medical advice for individual problems.   Appropriate medical professionals should be consulted regarding addiction and addiction recovery.   Pharmacologic Agents Clinical Signs and Symptoms Comments Drugs That Decrease Methadone Levels Rifampin, phenytoin, carbamazepine, butabarbital sodium, mephobarbital, phenobarbital, secobarbital, ethanol (chronic), disulfiram, urinary acidifiers, ascorbic acid Withdrawal signs Disulfiram…

  • Single State Agencies

    Admin 07/02/2022

    Alabama Department of Mental Health and Mental Retardation Division of Substance Abuse Services Webpage Alaska Division of Behavioral Health Webpage Arizona Bureau of Substance Abuse Treatment and Prevention Services Webpage Arkansas Division of Behavioral Health Services Alcohol and Drug Abuse Prevention Website California Dept of Alcohol and Drug Programs Website Colorado Dept of Human Services…